Source link : https://newshealth.biz/health-news/oral-breast-cancer-drug-wins-broader-fda-nod-for-esr1-mutated-disease/
(MedPage Today) — The FDA approved the oral estrogen receptor antagonist imlunestrant (Inluriyo) for previously treated ESR1-mutated advanced/metastatic breast cancer, the agency announced Thursday. The approval stipulates use in adults with… Source link : https://www.medpagetoday.com/hematologyoncology/breastcancer/117650 Author : Publish date : 2025-09-25 21:21:00 Copyright for syndicated content belongs to the linked Source.
The post Oral Breast Cancer Drug Wins Broader FDA Nod for ESR1-Mutated Disease first appeared on News Health.
—-
Author : News Health
Publish date : 2025-09-25 21:21:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8